|
OKUYAMA Ryo
Department Ritsumeikan Asia Pacific University College of International Management Position Professor |
|
| Language | English |
| Publication Date | 2023/05 |
| Type | Research paper |
| Peer Review | Peer reviewed |
| Title | Strengthening the Competitiveness of Japan’s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan’s Highly Productive Firm. |
| Contribution Type | Single Work |
| Journal | Biological and Pharmaceutical Bulletin |
| Journal Type | Another Country |
| Publisher | The Pharmaceutical Society of Japan |
| Volume, Issue, Page | 46(5),pp.718-724 |
| Total page number | 7 |
| Authorship | Lead author,Corresponding author |
| Author and coauthor | Ryo Okuyama |
| Details | The author found that bio-ventures established in the 1990s and 2000s played a crucial role in creating new drugs approved by the FDA from 2017 to 2022 in regions outside of Japan. In contrast, in Japan, all approved drugs were created by old incumbent pharmaceutical companies, highlighting the urgent need to foster drug discovery start-ups in Japan. A case study of the Japanese company that created the largest number of FDA-approved drugs suggests that focused investment in modality technology development, strengthening collaboration with academia in biology, and the reutilizing small-molecule drug discovery capabilities are essential for improving drug discovery productivity. |
| DOI | https://doi.org/10.1248/bpb.b23-00107 |